A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection.

Trial Profile

A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs XTL 6865 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors XTL Biopharmaceuticals
  • Most Recent Events

    • 29 Mar 2007 Status changed from recruiting to completed.
    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top